New mechanistic work ties gene regulation and immune escape to real resistance phenotypes. A study reports that DNA methylation silences components of the TRAIL apoptosis pathway—DR5, DcR2 and caspase-3—helping explain why breast cancer cells dodge TRAIL therapy, while pointing to methylation-based biomarkers and reversible targets. In melanoma and broader oncologic immune biology, another study shows the viral RNA sensor MDA5 can act as an immune-evading ally for tumors; disabling it triggers immunogenic cell death and improves checkpoint blockade responses across cancer types. The result connects innate sensing pathways to clinical immunotherapy outcomes. Finally, research in prostate cancer highlights circulating tumor vulnerabilities emerging from tumor biology: a meta-level view is supported by additional work showing that targeted blood-based approaches can stratify aggressive disease, but the mechanistic theme remains that resistance often comes from regulatory switches that can be mapped and potentially reversed.